Immunome, Inc.
IMNM
$20.92
$0.211.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | 69.84% | 184.35% | -28.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | 69.84% | 184.35% | -28.44% |
| Cost of Revenue | 6.01% | 32.24% | 39.09% | 139.91% | 396.94% |
| Gross Profit | -12.44% | -43.46% | -36.37% | -136.72% | -677.01% |
| SG&A Expenses | 15.75% | 14.90% | 43.91% | 78.02% | 29.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.76% | 28.70% | 40.02% | 122.52% | 230.01% |
| Operating Income | -13.06% | -37.25% | -37.93% | -119.40% | -301.40% |
| Income Before Tax | 12.90% | -21.99% | -20.14% | 67.84% | 13.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.90% | -21.99% | -20.14% | 67.84% | 13.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.90% | -21.99% | -20.14% | 67.84% | 13.37% |
| EBIT | -13.06% | -37.25% | -37.93% | -119.40% | -301.40% |
| EBITDA | -12.85% | -37.19% | -38.29% | -118.08% | -302.54% |
| EPS Basic | 42.35% | 16.50% | 17.24% | 79.13% | 41.01% |
| Normalized Basic EPS | 25.00% | 2.62% | -0.29% | -54.07% | -204.34% |
| EPS Diluted | 42.51% | 16.50% | 17.24% | 79.13% | 40.84% |
| Normalized Diluted EPS | 25.00% | 2.62% | -0.29% | -54.07% | -204.34% |
| Average Basic Shares Outstanding | 51.07% | 46.10% | 45.17% | 54.06% | 46.85% |
| Average Diluted Shares Outstanding | 51.07% | 46.10% | 45.17% | 54.06% | 46.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |